300158 振东制药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-0.031-8.545-29.934-0.843-0.769
总资产报酬率 ROA (%)-0.023-6.269-23.803-0.691-0.616
投入资产回报率 ROIC (%)-0.029-8.092-28.856-0.807-0.728

边际利润分析
销售毛利率 (%)53.72550.05747.49050.37549.314
营业利润率 (%)0.608-9.520-24.055-0.827-0.159
息税前利润/营业总收入 (%)0.643-9.925-44.301-1.3030.126
净利润/营业总收入 (%)-0.183-10.890-44.863-1.320-1.529

收益指标分析
经营活动净收益/利润总额(%)-298.310117.45431.235401.7133,667.027
价值变动净收益/利润总额(%)21.736-4.4557.412-119.491-1,250.833
营业外收支净额/利润总额(%)-33.8714.56945.65120.453-12.118

偿债能力分析
流动比率 (X)2.3192.1012.5624.8644.038
速动比率 (X)1.7111.5891.9443.5603.150
资产负债率 (%)26.04028.39826.54116.76920.266
带息债务/全部投入资本 (%)7.1265.6692.0841.2112.893
股东权益/带息债务 (%)1,287.2471,643.0784,613.8667,972.6533,282.543
股东权益/负债合计 (%)287.425255.144279.601499.702395.756
利息保障倍数 (X)3.409-194.9581,087.7644.9400.471

营运能力分析
应收账款周转天数 (天)105.15477.51769.33666.03076.499
存货周转天数 (天)195.355184.655227.454227.064191.597